REGN Stock Undervalued At $500?

Regeneron Pharmaceuticals (REGN) shares fell 19% after its COPD treatment, itepekimab, failed in a late-stage trial, impacting peak sales projections of $2-6 billion; this compounds existing pressures from weaker-than-expected Eylea sales and an FDA rejection of an Eylea HD pre-filled syringe. Despite the setback, the article suggests REGN is undervalued based on price-to-sales, price-to-free cash flow, and price-to-earnings ratios compared to the S&P 500, with strong profitability and financial stability metrics, and potential upside from Dupixent sales and a robust pipeline, presenting a possible buying opportunity for long-term gains, though clinical trial and macroeconomic risks remain.

Analysis

Regeneron Pharmaceuticals (REGN) experienced a significant 19% share price decline on May 30 following the late-stage clinical trial failure of itepekimab, its potential blockbuster COPD treatment developed with Sanofi, which had peak sales projections between $2 billion and $6 billion. This setback exacerbates existing pressures on REGN, which has fallen 60% from its 52-week high of approximately $1,200 to $490, partly due to weaker-than-anticipated Eylea performance and a recent FDA rejection of an Eylea HD pre-filled syringe variant due to third-party supplier issues. Despite these challenges, the stock appears undervalued from a valuation perspective. REGN's price-to-sales ratio is 4.6 versus 3.0 for the S&P 500, its price-to-free cash flow ratio is 16.4 compared to 20.5 for the S&P 500, and its price-to-earnings ratio is 14.4 against the benchmark's 26.4. While Regeneron's revenues have contracted at an average rate of 3.9% over the last three years, they grew 7.5% in the past 12 months to $14 billion, though quarterly revenues decreased 3.7% to $3.0 billion. Profitability remains very strong, with an operating margin of 27.2%, an operating cash flow margin of 28.1%, and a net income margin of 31.9%, all significantly outpacing S&P 500 averages. Financially, Regeneron is exceptionally stable, with a low debt-to-equity ratio of 4.2% and a solid cash-to-assets ratio of 22.2%. The company has shown neutral downturn resilience, performing slightly better than the S&P 500 in recent market shocks. Despite the itepekimab trial failure likely delaying its launch, strong growth from Dupixent (sales up 19% to $3.7 billion last quarter, potential peak annual sales over $20 billion) and a robust pipeline with over a dozen late-stage programs offer future growth prospects. The article suggests the current selling pressure below $500 is excessive, presenting a potential buying opportunity.

Key Decisions for Investors

• Investors may consider the current depressed stock price as a potential buying opportunity for long-term gains, given the company's strong underlying financial health and positive outlook for Dupixent and its broader pipeline, despite recent setbacks.
• Closely monitor developments related to ongoing clinical trials, particularly for itepekimab and other pipeline candidates, as well as sales trends for Eylea, as these will be key determinants of future stock performance.
• Be prepared for continued stock volatility due to clinical trial outcomes and broader macroeconomic conditions; investors seeking lower volatility might consider diversified approaches or await further clarity on pipeline progression before significantly increasing exposure.